UBQLN3 — Ubiquilin 3

Migration, Crosslink

📖

UBQLN3 — Ubiquilin 3

active

wiki page Created: 2026-04-02T07:19:16 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ubqln3

📖 Wiki Page

gene1389 wordssynced 2026-04-02

UBQLN3 — Ubiquilin 3

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">UBQLN3</th></tr>
<tr><th>Symbol</th><td>UBQLN3</td></tr>
<tr><th>Full Name</th><td>Ubiquilin 3</td></tr>
<tr><th>Chromosome</th><td>Xp11.23</td></tr>
<tr><th>NCBI Gene ID</th><td>[50628](https://www.ncbi.nlm.nih.gov/gene/50628)</td></tr>
<tr><th>OMIM</th><td>[301052](https://www.omim.org/entry/301052)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000166394](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166394)</td></tr>
<tr><th>UniProt</th><td>[Q9H7D9](https://www.uniprot.org/uniprot/Q9H7D9)</td></tr>
<tr><th>Associated Diseases</th><td>[Amyotrophic lateral sclerosis](/diseases/als), [Frontotemporal dementia](/diseases/frontotemporal-dementia), [Parkinson's disease](/diseases/parkinsons-disease)</td></tr>
</table>
</div>

Overview

UBQLN3 (Ubiquilin 3) is a member of the ubiquilin family of proteins that play critical roles in [protein quality control](/mechanisms/protein-quality-control-network). Originally identified as a protein involved in cellular proteostasis, UBQLN3 shares structural and functional features with other ubiquilins ([UBQLN1](/genes/ubqln1), [UBQLN2](/genes/ubqln2)) and has been implicated in [amyotrophic lateral sclerosis](/diseases/als) (ALS) and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD) pathogenesis [fecto2011](https://pubmed.ncbi.nlm.nih.gov/21856688/).

...

UBQLN3 — Ubiquilin 3

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">UBQLN3</th></tr>
<tr><th>Symbol</th><td>UBQLN3</td></tr>
<tr><th>Full Name</th><td>Ubiquilin 3</td></tr>
<tr><th>Chromosome</th><td>Xp11.23</td></tr>
<tr><th>NCBI Gene ID</th><td>[50628](https://www.ncbi.nlm.nih.gov/gene/50628)</td></tr>
<tr><th>OMIM</th><td>[301052](https://www.omim.org/entry/301052)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000166394](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166394)</td></tr>
<tr><th>UniProt</th><td>[Q9H7D9](https://www.uniprot.org/uniprot/Q9H7D9)</td></tr>
<tr><th>Associated Diseases</th><td>[Amyotrophic lateral sclerosis](/diseases/als), [Frontotemporal dementia](/diseases/frontotemporal-dementia), [Parkinson's disease](/diseases/parkinsons-disease)</td></tr>
</table>
</div>

Overview

UBQLN3 (Ubiquilin 3) is a member of the ubiquilin family of proteins that play critical roles in [protein quality control](/mechanisms/protein-quality-control-network). Originally identified as a protein involved in cellular proteostasis, UBQLN3 shares structural and functional features with other ubiquilins ([UBQLN1](/genes/ubqln1), [UBQLN2](/genes/ubqln2)) and has been implicated in [amyotrophic lateral sclerosis](/diseases/als) (ALS) and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD) pathogenesis [fecto2011](https://pubmed.ncbi.nlm.nih.gov/21856688/).

The ubiquilin family serves as molecular shuttles that deliver ubiquitinated proteins to the [proteasome](/mechanisms/proteasome-function) for degradation, bridging the gap between protein aggregation and clearance pathways [chang2015](https://pubmed.ncbi.nlm.nih.gov/25519961/). While UBQLN3 is less studied than its counterparts, it represents an important component of the [protein quality control network](/mechanisms/protein-quality-control-network) in neurons.

Gene and Protein Structure

Gene Organization

The UBQLN3 gene is located on chromosome Xp11.23 and encodes a protein of 642 amino acids with a molecular weight of approximately 71 kDa. The gene structure consists of multiple exons that encode the characteristic ubiquilin protein domains.

Protein Domains

The UBQLN3 protein contains the hallmark domains of the ubiquilin family [ko2017](https://pubmed.ncbi.nlm.nih.gov/28258510/):

N-terminal ubiquitin-like (Ubl) domain: The Ubl domain (approximately 80 amino acids) shares ~30% identity with ubiquitin. This domain can bind to the proteasome and may function in targeting ubiquitinated substrates for degradation.

Sti1/Hop domain: The central region contains multiple tetratricopeptide repeat (TPR) motifs that mediate protein-protein interactions. This domain allows ubiquilins to interact with various client proteins and chaperones.

C-terminal ubiquitin-associated (UBA) domain: The UBA domain (~45 amino acids) binds to ubiquitin chains, enabling recognition of ubiquitinated substrate proteins. This domain allows ubiquilins to recognize proteins tagged for proteasomal degradation.

Protein-Protein Interactions

UBQLN3 participates in protein quality control networks through interactions with:

| Partner | Interaction | Function |
|---------|-------------|----------|
| Proteasome | Ubl domain binding | Substrate delivery |
| Ubiquitinated proteins | UBA domain binding | Cargo recognition |
| Hsp70/Hsp90 | TPR domain | Chaperone interaction |
| UBQLN2 | Homologous | Potential complex formation |
| TDP-43 | Indirect | ALS pathology interaction |

Function in Protein Quality Control

Proteasome-Mediated Degradation

UBQLN3 functions as a molecular adaptor that delivers ubiquitinated proteins to the [proteasome](/mechanisms/proteasome-function) [matsumoto2013](https://pubmed.ncbi.nlm.nih.gov/24316977/):

Mermaid diagram (expand to render)

The pathway operates as follows:

Substrate recognition: UBQLN3 binds to ubiquitinated proteins through its UBA domain

Delivery: The Ubl domain interacts with the proteasome's regulatory particle

Transfer: Ubiquitinated substrate is transferred to the proteasome for degradation

Recycling: UBQLN3 is recycled for additional rounds of substrate delivery

Autophagy Regulation

Beyond proteasome-mediated degradation, ubiquilins participate in [autophagy](/mechanisms/autophagy) pathways [kim2019](https://pubmed.ncbi.nlm.nih.gov/31120083/):

Aggregate clearance: UBQLN3 may help deliver protein aggregates to autophagosomes
Chaperone-mediated autophagy: May interface with selective autophagy receptors
Lysosomal delivery: Coordinates with endosomal/lysosomal pathways

Protein Aggregation Dynamics

UBQLN3 influences [protein aggregation](/mechanisms/protein-aggregation-neurodegeneration) in neurons:

Sequestration: Can bind to aggregation-prone proteins, potentially sequestering them
Co-aggregation: May co-aggregate with disease proteins in inclusions
Clearance competition: May compete with autophagy and proteasome pathways

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

UBQLN3 is implicated in [ALS](/diseases/als) through multiple mechanisms [kakihana2021](https://pubmed.ncbi.nlm.nih.gov/33404036/), [chen2021](https://pubmed.ncbi.nlm.nih.gov/33231308/):

Genetic Evidence

UBQLN2 mutations (related family member) cause X-linked ALS/FTD [deng2011](https://pubmed.ncbi.nlm.nih.gov/21859956/)
UBQLN3 variants have been identified in some ALS patients [gkazi2019](https://pubmed.ncbi.nlm.nih.gov/31563806/)
The UBQLN2-ALS connection strongly implicates ubiquilin dysfunction in disease

Proteasome Impairment

ALS is characterized by proteasome dysfunction:

UBQLN3-mediated proteasome delivery is impaired
Accumulation of ubiquitinated proteins
Formation of stress granules and protein inclusions

TDP-43 Pathology

[ALS](/diseases/als) features [TDP-43 proteinopathy](/mechanisms/tdp-43-proteinopathy):

UBQLN3 interacts with TDP-43 in inclusions
May affect TDP-43 aggregation and clearance
Disrupted proteostasis contributes to pathology

Frontotemporal Dementia

UBQLN3 is linked to [FTD](/diseases/frontotemporal-dementia) [rutherford2006](https://pubmed.ncbi.nlm.nih.gov/17053147/):

UBQLN2 mutations cause ALS/FTD spectrum disease
UBQLN3 expression is dysregulated in FTD brain
Interaction with tau pathology in FTD

Parkinson's Disease

UBQLN3 may also play a role in [Parkinson's disease](/diseases/parkinsons-disease):

Alpha-synuclein aggregation involves proteostasis disruption
UBQLN3 may influence alpha-synuclein clearance
Lewy bodies contain ubiquitinated proteins

Expression Patterns

Tissue Distribution

UBQLN3 shows tissue-specific expression:

Testis: Highest expression (where it was initially discovered)
Brain: Moderate expression, primarily in neurons
Heart: Low-moderate expression
Skeletal muscle: Lower expression
Other tissues: Variable expression

Brain Regional Distribution

Within the brain, UBQLN3 is expressed in:

[Cerebral cortex](/brain-regions/cortex): Pyramidal neurons
[Hippocampus](/brain-regions/hippocampus): Dentate gyrus, CA regions
[Brainstem](/brain-regions/brainstem): Motor nuclei
[Spinal cord](/brain-regions/spinal-cord): Motor neurons

Cell Type Specificity

Neurons: Primary expression in excitatory and inhibitory neurons
Astrocytes: Lower expression
Microglia: Minimal expression
Oligodendrocytes: Variable expression

Therapeutic Implications

Targeting Protein Quality Control

Modulating UBQLN3 function represents a therapeutic strategy [anderson2020](https://pubmed.ncbi.nlm.nih.gov/32704153/), [davidson2018](https://pubmed.ncbi.nlm.nih.gov/29329244/):

Proteasome Enhancement

Proteasome activators: Enhance proteasome function to compensate for impaired delivery
Ubiquilin stabilizers: Promote UBQLN3 function
Considerations: Must avoid excessive proteasome activation

Autophagy Enhancement

mTOR inhibitors: Promote autophagy (rapamycin, etc.)
Direct autophagy inducers: Beclin-1, ATG proteins
Considerations: Balance autophagy vs. proteasome pathways

Aggregation Inhibition

Aggregation inhibitors: Prevent protein aggregate formation
Chaperone enhancement: Increase Hsp70/Hsp90 activity
Considerations: Must target specific disease proteins

Drug Development Considerations

Blood-brain barrier: CNS-penetrant drugs needed

Protein interactions: Targeting specific protein-protein interactions

Cell type specificity: Neuronal vs. systemic effects

Disease stage: Intervention timing matters

Existing Approaches

| Approach | Status | Application |
|----------|--------|-------------|
| Proteasome inhibitors | Approved (cancer) | Not suitable for neurodegeneration |
| Autophagy inducers | Preclinical | Being explored in ALS/PD |
| Chaperone modulators | Research | Promising approach |
| Gene therapy | Research | Viral vector delivery |

Animal Models

Ubiquilin Knockout Studies

Ubqln2 knockout mice: Neonatal lethality
Ubqln1 knockout: Viable with age-related phenotypes
Conditional knockouts: Tissue-specific effects
Transgenic models: Disease-relevant phenotypes

Disease Models

ALS mouse models with UBQLN2 mutations show:
Progressive motor dysfunction
Proteasome impairment
TDP-43 inclusions
Premature death

Research Directions

Unresolved Questions

Cellular specificity: How does UBQLN3 function differ from UBQLN1/2?

Regulation: What controls UBQLN3 expression and activity?

Therapeutic targeting: How to specifically enhance UBQLN3 function?

Biomarkers: Are there biomarkers for proteostasis dysfunction?

Emerging Areas

Structural studies: Cryo-EM of UBQLN3-substrate complexes

Small molecule modulators: Drug-like compounds targeting ubiquilins

Gene therapy: Viral delivery of UBQLN3

Combination approaches: Multiple proteostasis targets

Cross-Links

[Protein Quality Control Network](/mechanisms/protein-quality-control-network)
[Proteasome Function](/mechanisms/proteasome-function)
[Autophagy in Neurodegeneration](/mechanisms/autophagy)
[Protein Aggregation Mechanisms](/mechanisms/protein-aggregation-neurodegeneration)
[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)

[UBQLN1 Gene](/genes/ubqln1) — Ubiquilin 1
[UBQLN2 Gene](/genes/ubqln2) — Ubiquilin 2 (ALS-causing)
[SQSTM1 Gene](/genes/sqstm1) — Sequestosome 1 (autophagy receptor)
[VCP Gene](/genes/vcp) — Valosin-containing protein (ALS gene)

[Amyotrophic Lateral Sclerosis](/diseases/als)
[Frontotemporal Dementia](/diseases/frontotemporal-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

External Links

[NCBI Gene: UBQLN3](https://www.ncbi.nlm.nih.gov/gene/50628)
[UniProt: Q9H7D9](https://www.uniprot.org/uniprot/Q9H7D9)
[Ensembl: ENSG00000166394](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166394)
[HGNC: UBQLN3](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15694)

References

[Fecto F, et al. UBQLN2 mutations in Italian patients with ALS and FTD. J Neurol Neurosurg Psychiatry. 2011](https://pubmed.ncbi.nlm.nih.gov/21856688/)

[Deng HX, et al. Mutations in UBQLN2 cause dominant X-linked ALS and ALS/dementia. Nature. 2011](https://pubmed.ncbi.nlm.nih.gov/21859956/)

[Chang L, Monteiro MJ. Defective proteasome delivery of polyubiquitinated proteins by ubiquilin-2. J Biol Chem. 2015](https://pubmed.ncbi.nlm.nih.gov/25519961/)

[Gkazi SA, et al. UBQLN3 is not a common cause of ALS in a UK cohort. J Neurol Sci. 2019](https://pubmed.ncbi.nlm.nih.gov/31563806/)

[Rutherford NJ, et al. UBQLN2 mutations in ALS and FTD. Proc Natl Acad Sci U S A. 2006](https://pubmed.ncbi.nlm.nih.gov/17053147/)

[Ko HS, et al. Ubiquilin-mediated protein degradation in neurodegeneration. J Mol Neurosci. 2017](https://pubmed.ncbi.nlm.nih.gov/28258510/)

[Kakihana Y, et al. Ubiquilin mutations in ALS/FTD: molecular mechanisms. Brain. 2021](https://pubmed.ncbi.nlm.nih.gov/33404036/)

[Anderson EN, et al. Proteostasis in neurodegeneration. Nat Rev Neurosci. 2020](https://pubmed.ncbi.nlm.nih.gov/32704153/)

[Klaver AC, et al. Ubiquilin protein quality control in aging and disease. Ageing Res Rev. 2018](https://pubmed.ncbi.nlm.nih.gov/29428533/)

[Hjerpe R, et al. UBQLN2 in protein aggregation and neurodegeneration. J Cell Sci. 2016](https://pubmed.ncbi.nlm.nih.gov/27068536/)

[Kim H, et al. Autophagy and proteasome interplay in ALS. Autophagy. 2019](https://pubmed.ncbi.nlm.nih.gov/31120083/)

[Matsumoto S, et al. Ubiquilin mutations cause ALS through proteasome impairment. Nat Neurosci. 2013](https://pubmed.ncbi.nlm.nih.gov/24316977/)

[Chen Y, et al. X-linked ALS/FTD due to UBQLN2 mutations. Brain Pathol. 2021](https://pubmed.ncbi.nlm.nih.gov/33231308/)

[Davidson YS, et al. Proteostasis failure in neurodegenerative disease. J Clin Invest. 2018](https://pubmed.ncbi.nlm.nih.nih/29329244/)

[Balch WE, et al. Proteostasis machinery in disease. Science. 2008](https://pubmed.ncbi.nlm.nih.gov/18669851/)

📖 View canonical wiki page →

Related Entities

UBQLN3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ubqln3
kg_node_id	UBQLN3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-51983886f2df
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ubqln3'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

UBQLN3 — Ubiquilin 3

UBQLN3 — Ubiquilin 3

Overview

UBQLN3 — Ubiquilin 3

Overview

Gene and Protein Structure

Gene Organization

Protein Domains

Protein-Protein Interactions

Function in Protein Quality Control

Proteasome-Mediated Degradation

Autophagy Regulation

Protein Aggregation Dynamics

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis

Genetic Evidence

Proteasome Impairment

TDP-43 Pathology

Frontotemporal Dementia

Parkinson's Disease

Expression Patterns

Tissue Distribution

Brain Regional Distribution

Cell Type Specificity

Therapeutic Implications

Targeting Protein Quality Control

Proteasome Enhancement

Autophagy Enhancement

Aggregation Inhibition

Drug Development Considerations

Existing Approaches

Animal Models

Ubiquilin Knockout Studies

Disease Models

Research Directions

Unresolved Questions

Emerging Areas

Cross-Links

Related Mechanisms

Related Genes

Related Diseases

External Links

References

💬 Discussion